<div id="readability-page-1"><p>Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) dropped 5% on Thursday . The stock traded as low as $3.57 and last traded at $3.5450. Approximately 366,023 shares were traded  during mid-day trading, a decline of 86% from the average daily volume of 2,568,063 shares. The stock had previously closed at $3.73.</p><h2>Wall Street Analysts Forecast Growth</h2><p>Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, August 9th. Zacks Research cut Ironwood Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, November 4th. Wells Fargo &amp; Company upped their target price on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Tuesday, November 11th. Finally, Weiss Ratings  reissued a &#34;sell (d)&#34; rating on shares of Ironwood Pharmaceuticals in a research report on Monday. One equities research analyst  has rated the stock with a Buy rating, six have assigned  a Hold rating and one  has issued  a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock  has an average rating of &#34;Hold&#34; and an average target price of $5.34.</p><p><b>Read Our Latest Stock Report on IRWD</b></p><h2>Ironwood Pharmaceuticals Stock Performance</h2><p>The company's 50 day moving average price is $2.21 and its 200-day moving average price is $1.35. The stock has a market cap of $578.65 million, a P/E ratio of 22.30 and a beta of 0.18. </p><p>Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.15. The business had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%.  On average, analysts forecast that  Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year. </p><h2>Institutional Investors Weigh In On Ironwood Pharmaceuticals</h2><p>Large investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC lifted its position in shares of  Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company's stock valued at $25,000 after buying an additional 3,406 shares during the last quarter.  McAdam LLC purchased a new stake in  Ironwood Pharmaceuticals during the first quarter valued at about $40,000.  Vise Technologies Inc. bought a new position in  Ironwood Pharmaceuticals during the third quarter worth about $39,000.  BNP Paribas Financial Markets increased its stake in shares of  Ironwood Pharmaceuticals by 83.2% in the third quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 15,594 shares in the last quarter.  Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of  Ironwood Pharmaceuticals in the second quarter valued at approximately $25,000. </p><h2>Ironwood Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.</p><h2>Read More</h2><ul><li>Five stocks we like better than Ironwood Pharmaceuticals</li><li>Business Services Stocks Investing</li><li>Wolfspeed Just Got a $698 Million Lifeline—Here’s Why That Changes Everything</li><li>What is the Dogs of the Dow Strategy? Overview and Examples</li><li>Uber Gets a Street-High Upgrade as Robotaxis Roll Out in Dallas</li><li>What is Put Option Volume?</li><li>Investors Were Dead Wrong About Box—This AI-Driven Comeback Just Proved It</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Ironwood Pharmaceuticals Right Now?</h2><p>Before you consider Ironwood Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ironwood Pharmaceuticals wasn't on the list.</p><p>While Ironwood Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IRWD

<p>Ironwood Pharmaceuticals' stock dropped 5% to $3.5450, with trading volume down 86% from the average. Analysts have mixed ratings: Wall Street Zen upgraded to "strong-buy," Zacks downgraded to "hold," and Weiss Ratings issued a "sell." The stock has a "Hold" average rating with a $5.34 target price. Recent earnings exceeded expectations, with $0.24 EPS and $122.06 million revenue. Institutional investors have adjusted their holdings, with some increasing stakes. Ironwood focuses on GI products, marketing linaclotide under LINZESS and CONSTELLA names.</p>

Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5% - Time to Sell?